Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q

Riener, Marc‐Oliver; Nikolopoulos, Elisabeth; Herr, Alexander; Wild, Peter J.; Hausmann, Michael; Wiech, Thorsten; Orlowska-Volk, Marzenna; Laßmann, Silke; Walch, Axel; Werner, Martin

doi:10.1016/j.humpath.2008.02.021

Cited by 32 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many genes demonstrate tumor-specific methylation (Esteller, 2002;Ongenaert et al, 2008), there is no single methylation marker that would provide satisfactory clinical performance (Tsou et al, 2007;Wentzensen et al, 2009). In the case of CDH13, instances of both hypermethylation and loss of function have been documented in breast (Riener et al, 2008) and lung cancers (Sato et al, 1998a,b;Toyooka et al, 2001a), in pituitary adenomas , diffuse large B cell lymphoma (Ogama et al, 2004), nasopharyngeal carcinoma (Sun et al, 2007), and cutaneous squamous cell carcinomas (Takeuchi et al, 2002b). CDH13 has been High level of expression in a separate study (Buechner et al, 2009).…”

Section: Cdh13 Epigenetic Silencing In Cancer Cellsmentioning

confidence: 98%

Cadherin 13 in cancer

Андреева

Kutuzov

2010

Genes Chromosomes & Cancer

118

113

View full text Add to dashboard Cite

We review the evidence suggesting the involvement of Cadherin 13 (CDH13, T-cadherin, H-cadherin) in various cancers. CDH13 is an atypical member of the cadherin family, devoid of a transmembrane domain and anchored to the exterior surface of the plasma membrane via a glycosylphosphatidylinositol anchor. CDH13 is thought to affect cellular behavior largely through its signaling properties. It is often down-regulated in cancerous cells. CDH13 down-regulation has been associated with poorer prognosis in various carcinomas, such as lung, ovarian, cervical and prostate cancer. CDH13 re-expression in most cancer cell lines inhibits cell proliferation and invasiveness, increases susceptibility to apoptosis, and reduces tumor growth in in vivo models. These properties suggest that CDH13 may represent a possible target for therapy in some cancers. At the same time, CDH13 is up-regulated in blood vessels growing through tumors and promotes tumor neovascularization. In contrast to most cancer cell lines, CDH13 overexpression in endothelial cells promotes their proliferation and migration, and has a pro-survival effect. We also discuss molecular mechanisms that may regulate CDH13 expression and underlie its roles in cancer.

show abstract

Section: Cdh13 Epigenetic Silencing In Cancer Cellsmentioning

confidence: 98%

Cadherin 13 in cancer

Андреева

Kutuzov

2010

Genes Chromosomes & Cancer

118

113

View full text Add to dashboard Cite

show abstract

“…Downregulation of T-cadherin was shown to be associated with malignant phenotype and tumorigenecity in breast (Riener et al, 2008), lung (Sato et al, 1998), and gallbladder cancers (Adachi et al, 2009). However, in other cancers such as ovarian, endometrial (Widschwendter et al, 2004;Suehiro et al, 2008) and osteosarcoma (Zucchini et al, 2004) T-cadherin decreased expression correlated positively with patient survival.…”

Section: T-cadherin and Tumor Growth And Vascularizationmentioning

confidence: 99%

Malignant Transformation in Skin is Associated with the Loss of T-Cadherin Expression in Human Keratinocytes and Heterogeneity in T-Cadherin Expression in Tumor Vasculature

Рубина¹,

Sysoeva²,

Semina³

et al. 2012

Tumor Angiogenesis

View full text Add to dashboard Cite

“…It was shown that the expression of CDH13 could be down-regulated through hypermethylation of gene promoter region 11. Alterations, like promoter hypermethylation and loss of function of CDH13 gene have been detected in breast cancer 12 and lung cancer13-15, in pituitary adenoma16, diffuse large B cell lymphoma17, and nasopharyngeal carcinoma18. Moreover, CDH13 gene has been suggested as an promising early detecting marker for lung cancer 19.…”

Section: Introductionmentioning

confidence: 99%

Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma

Pu¹,

Geng²,

Chen³

et al. 2016

J. Cancer

View full text Add to dashboard Cite

Background: Aberrant methylation of CpG islands in tumor cells in promoter regions is a critical event in non-small cell lung carcinoma (NSCLC) tumorigenesis and can be a potential diagnostic biomarker for NSCLC patients. The present study systemically and quantitatively reviewed the diagnostic ability of CDH13 methylation in NSCLC as well as in its subsets. Eligible studies were identified through searching PubMed, Web of Science, Cochrane Library and Embase. The pooled odds of CDH13 promoter methylation in lung cancer tissues versus normal controls were calculated by meta-analysis method. Simultaneously, four independent DNA methylation datasets of NSCLC from TCGA and GEO database were downloaded and analyzed to validate the results from meta-analysis. Results: Thirteen studies, including 1850 samples were included in this meta-analysis. The pooled odds ratio of CDH13 promoter methylation in cancer tissues was 7.41 (95% CI: 5.34 to 10.29, P < 0.00001) compared with that in controls under fixed-effect model. In validation stage, 126 paired samples from TCGA were analyzed and 5 out of the 6 CpG sites in the CpG island of CDH13 were significantly hypermethylated in lung adenocarcinoma tissues but none of the 6 CpG sites was hypermethylated in squamous cell carcinoma tissues. Concordantly, the results from other three datasets, which were subsequently obtained from GEO database consisting of 568 tumors and 256 normal tissues, also consisted with those from TCGA dataset. Conclusion: The pooled data showed that the methylation status of the CDH13 promoter is strongly associated with lung adenocarcinoma. The CDH13 methylation status could be a promising diagnostic biomarker for diagnosis of lung adenocarcinoma.

show abstract

Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q

Cited by 32 publications

References 32 publications

Cadherin 13 in cancer

Cadherin 13 in cancer

Malignant Transformation in Skin is Associated with the Loss of T-Cadherin Expression in Human Keratinocytes and Heterogeneity in T-Cadherin Expression in Tumor Vasculature

Aberrant methylation of CDH13 can be a diagnostic biomarker for lung adenocarcinoma

Contact Info

Product

Resources

About